Business Wire

MA-VERACODE

23.5.2023 17:27:28 CEST | Business Wire | Press release

Share
Veracode Named a Leader in the Magic Quadrant™ Application Security Testing For 10th Consecutive Time

Veracode, a leading provider of intelligent software security solutions, has been positioned as a 10-time Leader in the 2023 Gartner Inc. Magic Quadrant for Application Security Testing—an in-depth evaluation of the market’s competitors. The company has been recognized as a Leader in the report every single time since it was first published.

With independent feedback and ratings from customer reviews culminating in a 97 percent “willingness to recommend” (based on 61 reviews, as of 31 July 2022), Veracode was also positioned as a Gartner Peer Insights™ Customers’ Choice for Application Security Testing.

Sam King, Chief Executive Officer at Veracode, said, “For more than 17 years, we have had an unrelenting commitment to making secure software a competitive advantage for our customers. Our continued position as a Leader in the Gartner Magic Quadrant, combined with our recognition as a Customers’ Choice, we feel demonstrates the trust placed in us every day by developers, security teams, and business leaders worldwide. We are proud to say that Veracode was one of the pioneers of application security and now we are propelling the category into the future: intelligent software security.”

The Head of Application Security at a banking company reviewing Veracode in Gartner Peer Insights™ said, “Of all the companies that carry out POCs (Proof of Concepts)...only Veracode proves to be a solid and senior company or enough to put in our financial institution." A security analyst at another firm commented, “In order for a product to be successful, it needs to do two things right, ‘product performance’ and ‘support’. Veracode gives you the best of both worlds, a great product with great support.”

Protecting the Software Supply Chain

Veracode offers EU and UK Support through its dedicated European Region, an EU instance that allows European organizations to address data residency concerns. The company has also achieved the US Federal Risk and Authorization Management Program (FedRAMP), which makes multiple tools available to US federal agencies that want to find and fix software supply chain vulnerabilities in accordance with compliance mandates. Veracode is the only software composition analysis vendor listed in the FedRAMP marketplace.

King said, “Increased reliance on third-party code, along with emerging regulations for software security and data compliance, are some of our customers’ greatest challenges. To alleviate the pressure on organizations, our proprietary database tracks open-source risk and our platform provides continuous scanning through multiple tools, including container security, infrastructure-as-code (IaC) scanning, and Software Bill of Materials (SBOM) capabilities.”

Veracode’s recent addition of Peer Benchmarking—a new self-service capability that allows organizations to measure their flaw and remediation performance against industry peers—also enables security leaders to assess the impact of their investments and demonstrate value to the business.

Strength of Vision: Delivering Capabilities Against Customer Needs

In the past year, Veracode has also made two significant acquisitions, to which the company credits its position in the report. Firstly, the acquisition of the Germany-based Crashtest Security tool enhanced Veracode’s existing dynamic analysis and penetration testing capabilities for web apps and application programming interfaces (APIs), as well as broadening customer access globally. More recently, the acquisition of auto-remediation technology from Jaroona, a 2021 Gartner® Cool Vendor™ for DevSecOps, enabled the launch of Veracode Fix. The new AI-powered product automatically suggests remediations for security flaws found in code and open-source dependencies.

Brian Roche, Chief Product Officer at Veracode, said, “One of the biggest pain points our customers express is mitigating intensifying threat against an expanding attack surface, while accelerating development velocity and minimizing costs. We’ve invested heavily in our platform over the past year to develop automated solutions that remove friction for developers and provide security teams with a comprehensive view of risk. The launch of Veracode Fix addresses the need to broaden our focus from application security testing to intelligent software security.”

To download a complimentary copy of the full 2023 Gartner Magic Quadrant Report, visit the Veracode website.

To learn more about intelligent software security from Veracode, please visit: https://www.veracode.com/products

1Gartner, Magic Quadrant for Application Security Testing, Mark Horvath, Dale Gardner, Manjunath Bhat, Ravisha Chugh, Angela Zhao, 17 May 2023.

2Gartner, “Peer Insights ‘Voice of the Customer’: Application Security Testing” by Peer Contributors, September 30, 2022.

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, Magic Quadrant, Cool Vendors and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

About Veracode

Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Prompted by powerful AI trained by trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.

Copyright © 2023 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005707/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye